<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>Ophthotech</title>
	<link>http://www.ophthotech.com</link>
	<description>Therapeutic Pharmaceuticals for Macular Degeneration</description>
	<lastBuildDate>Thu, 02 Feb 2012 14:52:23 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.2.1" -->

	<item>
		<title></title>
		<description><![CDATA[Ophthotech Corporation is a privately held, clinical-stage biotechnology company located in Princeton, NJ and New York, NY. Our experience and expertise with back of the eye diseases enables us to concentrate on developing and commercializing therapies for both dry and wet Age-Related Macular Degeneration (AMD) in an accelerated manner.]]></description>
		<link>http://www.ophthotech.com/ophthotech-corporation/</link>
			</item>
	<item>
		<title></title>
		<description><![CDATA[Press Release &#8211; January 3, 2012: Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference]]></description>
		<link>http://www.ophthotech.com/press-release-jan-3-201/</link>
			</item>
	<item>
		<title></title>
		<description><![CDATA[New Product Candidates About Ophthotech]]></description>
		<link>http://www.ophthotech.com/home-page-links/</link>
			</item>
	<item>
		<title>Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference</title>
		<description><![CDATA[Princeton, NJ and New York, NY &#8211; January 3, 2012 &#8211; Ophthotech Corp. announced today that the company will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Samir Patel, M.D., co-founder, president and chief executive officer of Ophthotech, will deliver a presentation on Jan. 11, 2012, at 10:30 a.m. PST in [...]]]></description>
		<link>http://www.ophthotech.com/ophthotech-to-present-at-jpm/</link>
			</item>
	<item>
		<title>Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration</title>
		<description><![CDATA[Anti-PDGF Aptamer E10030 to be Dosed in Combination with Lucentis&#174; Princeton, NJ &#8211; April 26, 2010 &#8211; Ophthotech Corp. (&#8220;Ophthotech&#8221;), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, [...]]]></description>
		<link>http://www.ophthotech.com/first-patient-phase-ii-10030/</link>
			</item>
	<item>
		<title>Ophthotech Raises $30 Million in Series B Financing</title>
		<description><![CDATA[&#8211;Company Plans to Initiate Phase 2 Combination Study with E10030 in Wet Age-related Macular Degeneration, Advance Two Additional Clinical State Programs in Macular Degeneration&#8211; NEW YORK, December 15, 2009 &#8212; Ophthotech Corp., a biopharmaceutical company focused on developing novel ophthalmic therapies for both wet and dry age-related macular degeneration (AMD), announced today that it has [...]]]></description>
		<link>http://www.ophthotech.com/series-b-financing/</link>
			</item>
	<item>
		<title>Positive Results for Ophthotech&#8217;s Novel Therapy for Wet AMD</title>
		<description><![CDATA[59% of patients showed 3-line gain (significant visual gain) and 100% neovascular regression Fort Lauderdale, Fla, May 4, 2009 &#8211; Ophthotech Corp. today announced positive results of a phase 1 clinical study evaluating E10030, its novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to treat wet age-related macular [...]]]></description>
		<link>http://www.ophthotech.com/positive-results/</link>
			</item>
	<item>
		<title></title>
		<description><![CDATA[Ophthotech Corp. 5 Vaughn Drive Suite 106 Princeton, NJ 08540 Phone (609) 945-6050 Fax (609) 452-7435 Map &#38; Directions &#160; Ophthotech Corp. One Penn Plaza 35th Floor New York, NY 10119 Phone (212) 845-8200 Fax (212) 845-8250 Map &#38; Directions]]></description>
		<link>http://www.ophthotech.com/316/</link>
			</item>
	<item>
		<title>SV Life Sciences</title>
		<description><![CDATA[SV Life Sciences was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. The company&#8217;s first fund closed in 1994 raising $100m. SV Life Sciences now has four funds with current committed capital of more than $900m. Its team of 29 professionals are located in offices in [...]]]></description>
		<link>http://www.ophthotech.com/sv-life-sciences/</link>
			</item>
	<item>
		<title>Clarus Ventures</title>
		<description><![CDATA[Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds that have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and key decision makers allow this team to identify unique investment [...]]]></description>
		<link>http://www.ophthotech.com/clarus-ventures/</link>
			</item>
</channel>
</rss>

